Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO



Dr. Roberto Gallego-Pinazo, MD, PhD
Unit of Macula and Clinical Trials
Oftalvist Clinic Valencia in Spain

Dr. Gallego Pinazo specialized in diagnosis and management of retina diseases through a fellowship at VRM New York under the mentorship of Dr. Lawrence Yannuzzi in 2012.

He has published over 200 scientific papers in the field of macular and retinal diseases. Dr Gallego-Pinazo has acted as principal investigator in over 50 clinical trials on treatments for the main causes of blindness derived from retinal diseases, with new drugs, devices, and gene therapy.

Visual and anatomic outcomes with emerging neovascular AMD treatments


Nikolas London, MD, FACS
Retinal Consultants
San Diego, CA

Dr. London enjoys all aspects of his field and strives to provide excellent and compassionate care for all his patients. He stays abreast of all of the latest innovations and treatment options, regularly attending and presenting at national academic conferences. He has published dozens of articles and book chapters and serves as a reviewer for multiple academic journals. He also frequently lectures on Retinal disease across the country for physicians as well as locally for the optometric community and hospitals. Dr. London serves as the Principal Investigator for multiple clinical trials evaluating the next generation of surgical and medical treatment options. Lastly, Dr. London works closely with charity groups like Champions for Health to provide care to those unable to afford medical care.

In this episode, Dr. Nikolas London of Retina Consultants San Diego shared his perspective on treatment outcomes in neovascular AMD and discusses the latest data from the TENAYA and LUCERNE clinical trials.

Extending treatment interval with latest therapies in DMO


Nathan Steinle, MD
California Retina Consultants
Santa Barbara, California

Dr. Steinle has received numerous accolades including the honor of being named Chief Resident and earning the prestigious Wirtschafter Award recognizing the finest resident teacher. During his fellowship, he was also named the best teacher at the Cleveland Clinic. Further accolades include a Senior ASRS Honors Award for his scientific contributions, as well as an International Best of ARVO Award for his research. He is also an elected member of the renowned Retina Society. He has published numerous book chapters and research articles. Dr. Steinle serves on several global steering committees and is a principal investigator in a number of research trials including novel therapies for AMD and diabetes.

Dr. Nathan Steinle of California Retina Consultants discusses strategies to extend treatment Intervals for patients with diabetic macular oedema and advances in therapies with more durability.

Real-world evidence for neovascular AMD therapies


Jeremy D. Wolfe, MD, MS, FASRS
Associated Retinal Consultants
Royal Oak, Michigan

Dr. Wolfe is a board-certified ophthalmologist specializing in all aspects of vitreoretinal disease. He is a member of the American Academy of Ophthalmology, American Society of Retina Specialists, and the Association in Research of Vision and Ophthalmology. He has vast experience in the medical and surgical treatment of all retinal diseases such as macular degeneration, diabetic eye disease, and retinal vein occlusions. He performs advanced retinal surgery for many vitreoretinal diseases, including macular holes, epiretinal membranes, retinal detachments, and proliferative vitreoretinopathy. He is involved in numerous clinical trials and is able to provide the most sophisticated treatments available.

In this episode, Dr. Jeremy Wolfe of Associated Retinal Consultants discusses the real-world efficacy and safety of the latest therapies in neovascular AMD and findings from the ongoing TRUCKEE study.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.